Bayer to buy Perfuse Therapeutics in up to $2.45 billion deal

Bayer is set to acquire Perfuse Therapeutics in a deal valued up to $2.45 billion. This strategic move aims to enhance Bayer's eye care treatments. The acquisition includes PER-001, a promising drug for glaucoma and diabetic retinopathy currently in clinical trials. This development signifies a significant step forward in eye disease treatment.